课题基金 / 基金详情

Examining the impact of endogenous CD28 signaling on CAR T cells

Examining the impact of endogenous CD28 signaling on CAR T cells
检查内源性 CD28 信号传导对 CAR T 细胞的影响
批准号:
10113296
负责人:
Scott Henry Olejniczak
金额:
$8.41万
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
已结题
起止时间:
2020-12-11 至 2022-11-30

项目摘要

项目成果

Scott Henry Olejniczak的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Project Abstract/Summary. Recent advances in immune cell engineering have revolutionized the treatment of blood cancers. Genetic modification of T cells, whose physiological job is to kill infected and mutant cells throughout our bodies, with Chimeric Antigen Receptors (CARs) can redirect T cell killing activity against malignant cells that express certain target proteins on their surface. CARs are built to mimic physiological T cell signaling, which is unique in its requirement for two signals provided by the T cell receptor (TCR) and co-receptors, such as CD28, to induce T cell function. Recent clinical studies in multiple myeloma (MM), a common incurable blood cancer, have shown that CAR T cells are remarkably effective at treating patients who do not respond to standard of care chemotherapies. Despite this, most MM patients relapsed within a year of CAR T cell therapy and the cause of their relapses was not readily apparent. The long-term goal of the project proposed in this grant application is to use our knowledge or T cell signaling to make CAR T cell therapy for MM more effective. To this end, we have found that endogenous CD28 on CAR T cells disrupts their ability to kill MM cells that express CD28 stimulatory proteins CD80 and CD86. However, the same endogenous CD28 is essential for making CAR T cells and we have also found that the CD28 signal provided during the CAR T cell manufacturing process helps determine how good of tumor killers CAR T cells become. Proposed studies seek to 1) identify ways to manipulate CD28 signaling during CAR T cell manufacture that can improve their long-term ability to kill MM cells in patients, and 2) determine how endogenous CD28 signaling causes dysfunction of CAR T cells. Results of these studies will have direct clinical implications because adjustments to the CAR T cell manufacturing process could be rapidly implemented and a drug that blocks CD28 activation, abatacept, is already used to treat people suffering from rheumatoid arthritis.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Understanding mechanisms and consequences of T cell co-receptor regulated RNA maturation
  • 批准号:
    10096361
  • 项目类别:
  • 资助金额:
    $53.4万
  • 财政年份:
    2021
  • 负责人:
    Scott Henry Olejniczak
  • 依托单位:
Understanding mechanisms and consequences of T cell co-receptor regulated RNA maturation
  • 批准号:
    10589052
  • 项目类别:
  • 资助金额:
    $51.69万
  • 财政年份:
    2021
  • 负责人:
    Scott Henry Olejniczak
  • 依托单位:
Understanding mechanisms and consequences of T cell co-receptor regulated RNA maturation
  • 批准号:
    10383646
  • 项目类别:
  • 资助金额:
    $51.69万
  • 财政年份:
    2021
  • 负责人:
    Scott Henry Olejniczak
  • 依托单位:
Examining the impact of endogenous CD28 signaling on CAR T cells
  • 批准号:
    10318192
  • 项目类别:
  • 资助金额:
    $8.41万
  • 财政年份:
    2020
  • 负责人:
    Scott Henry Olejniczak
  • 依托单位:
国内基金
海外基金
The Heterogenous Impact of Monetary Policy on Firms' Risk and Fundamentals
基于ImPACT方案的家长干预对孤独症谱系障碍儿童干预疗效及神经生物学机制研究
  • 批准号:
    82301732
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    30万元
  • 批准年份:
    2023
  • 负责人:
    乐郊
  • 依托单位:
西方饮食通过“肠道菌群-Rspo1”轴促进肥胖与肠道吸收的机制研究
  • 批准号:
    82370845
  • 项目类别:
    面上项目
  • 资助金额:
    48.00万元
  • 批准年份:
    2023
  • 负责人:
    洪洁
  • 依托单位:
2型糖尿病胰岛β细胞功能调控新靶点IMPACT的功能及作用机制研究
  • 批准号:
    81600598
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    19.0万元
  • 批准年份:
    2016
  • 负责人:
    李锴
  • 依托单位: